Riferimento:
Nat Rev Endocrinol. 2010 Apr;6(4):188-9.
Autori:
Oberg K.
Fonte:
Nat Rev Endocrinol. 2010 Apr;6(4):188-9.
Anno:
2010
Azione:
Octreotide LAR (rilascio a lunga durata) ha un effetto antitumorale sostanziale, con la sopravvivenza libera da progressione più lunga rispetto al placebo nei pazienti con tumori neuroendocrini ben differenziati e bassa massa tumorale.
Target:
Octreotide LAR/tumori neuroendocrini ben differenziati e bassa massa tumorale.
ABSTRACT
Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The ProMid study group now reports that octreotide lar (long-acting release) has a substantial antitumor effect, with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden.
Sostanze: